RHEAGAN MOORE: Open Payments
NPI 1275157398 · MONROE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,499 in 131 payments from 19 companies in 2025. Trend: 2023 $155 · 2024 $281 · 2025 $2,499
Food & beverage: $2,499
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 21 | $466 |
| Novo Nordisk Inc | 23 | $392 |
| Bayer Healthcare Pharmaceuticals Inc. | 18 | $375 |
| Lilly USA, LLC | 13 | $208 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $185 |
| Corcept Therapeutics | 8 | $157 |
| Tandem Diabetes Care, Inc. | 6 | $130 |
| Insulet Corporation | 5 | $118 |
| Abbott Laboratories | 5 | $106 |
| Sequel Med Tech, LLC | 4 | $89 |
Products named: Dexcom G6 Transmitter, Kerendia, JARDIANCE, Ozempic, MOUNJARO, Rybelsus, Korlym, t:slim X2 Insulin Pump with Control-IQ.
Industry payments across LA — which companies pay providers there.
